This is a clean sweep for BSX — the patent is invalid and the product does not infringe. The case is over with no further appeal available to UT on the merits (the Federal Circuit reversed on both grounds). Traders should view this as a definitive removal of a multi-year litigation overhang. Monitor for any petition for certiorari to the Supreme Court, though the factual findings make that unlikely. No other near-term catalysts from this case.
Price Chart
Executive Summary
The Federal Circuit reversed the district court's denial of JMOL and ruled in favor of Boston Scientific (BSX) on all counts in a patent infringement suit brought by the University of Texas (UT). The court held that UT's patent claims were invalid for anticipation by prior art (Song patent) and that BSX's drug-eluting stent coating does not infringe because it is not a 'thread-like' fiber. This eliminates a material liability risk that had been hanging over BSX since a jury verdict in 2024, removing the threat of a reasonable-royalty damages award and any potential injunction on its coronary stent product line.
Court Ruling Details
Key Facts
- Federal Circuit reversed the district court's denial of JMOL, finding BSX entitled to judgment as a matter of law on both anticipation and noninfringement.
- The court held that UT's '296 patent claims are invalid for anticipation by the prior-art Song patent, which teaches a biodegradable polymer fiber with immiscible phases and varying release rates.
- The court also held that BSX's accused stent coating is not a 'thread-like' fiber under the claim construction, so there is no infringement.
- The ruling eliminates the jury's finding of infringement and the reasonable-royalty damages award (amount not stated in the opinion), as well as any risk of an injunction on BSX's drug-eluting coronary stent systems.
- Costs were awarded to BSX as the appellant.
Financial Impact
Eliminates an unspecified reasonable-royalty damages award from the jury verdict and removes any risk of an injunction on BSX's drug-eluting coronary stent product line. The damages amount is not stated in the opinion.
Risk Factors
- UT could petition for certiorari to the Supreme Court, though the Federal Circuit's factual findings on anticipation and noninfringement make reversal unlikely.
- No damages amount was specified in the opinion, so the exact financial exposure eliminated is unknown but the risk of an injunction on a major product line was material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 court opinions from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2b05bbc35d-BSX |
| COURT-RULING Data (Synthetic) | court-bcc5a3f50e-BSX |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $43.23 (−10.50%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $43.23 (+10.26%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $43.23 (−11.79%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $43.23 (−9.45%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $43.23 (+6.10%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $43.23 (−6.14%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $43.23 (−5.01%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $43.23 (−3.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access